At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3, Randomized, Adaptive Dose-Selection, Multi-regional, Double-Masked, Parallel-Group, 3-Month Trial Evaluating the Safety and Efficacy of NCX 470 vs. Latanoprost 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Mont Blanc)
In Brief
A Phase 3 clinical trial evaluating NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), and 3 other interventions for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 691 participants across 1 site.
Detailed Summary
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. In the adaptive dose selection phase of the trial, subjects will be randomized in a 1:1:1 ratio to one of two doses of NCX 470 (0.065% or 0.1%) or to latanoprost 0.005%. Following the selection of one dose of NCX 470, subjects will be randomized in a 1:1 ratio to the chosen dose of NCX 470 or to latanoprost 0.005%.
Study Details
Timeline
Interventions
NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)
Latanoprost Ophthalmic Solution, 0.005%
NCX 470 Ophthalmic Solution, 0.1%
NCX 470 Ophthalmic Solution, 0.1%
Latanoprost Ophthalmic Solution, 0.005%